Good point, he had time to chat to media about the US but not shareholders. How often is he chatting to analysts, media giving them heads up first before shareholders.
I think there is a class action based around keeping the market informed, would appear they still have not learnt.
When was the last time anyone heard from the company about a certain Chinese approval and what is occurring, is it on track, delayed due to covid, such a crucial element one would think a little heads up would be noce.
Us FDA may be only temporary but if you aint there you aint got a chance of being there when it is extended. Have a look at BUB announcment today, every chance in the world it will be permanent.
A2M Price at posting:
$4.50 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)